Small Cell Lung Cancer Clinical Trial
Official title:
Studying Patient Experiences in Small Cell Lung Cancer Clinical Trials to Identify Influencing Factors
| NCT number | NCT05769504 |
| Other study ID # | 86382894 |
| Secondary ID | |
| Status | Not yet recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | April 2024 |
| Est. completion date | April 2026 |
Clinical study participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future small cell lung cancer patients during clinical trials.
| Status | Not yet recruiting |
| Enrollment | 500 |
| Est. completion date | April 2026 |
| Est. primary completion date | April 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Aged = 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed. - Participant has a diagnosis of small cell lung cancer. - Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. Exclusion Criteria: - Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent. - Pregnant or lactating woman - Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Power Life Sciences Inc. |
Seto Z, Takata N, Murayama N, Tokui K, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Inomata M. Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer. Tumori. 2021 Dec;107(6):536-541. doi: 10.1177/0300891620974762. Epub 2020 Nov 25. — View Citation
van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011 Nov 12;378(9804):1741-55. doi: 10.1016/S0140-6736(11)60165-7. Epub 2011 May 10. — View Citation
Xing H, Zhang J, Ge F, Yu X, Bian H, Zhang F, Fang J. [Analysis of the Efficacy of Irinotecan in the Second-line Treatment of Refractory and Relapsed Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):167-172. doi: 10.3779/j.issn.1009-3419.2021.103.04. Chinese. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Rate of patients who decide to enroll in a small cell lung cancer clinical study. | 3 months | ||
| Primary | Number of small cell lung cancer patients who remain in clinical trial until completion. | 12 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03651219 -
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03958045 -
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
|
Phase 2 | |
| Completed |
NCT04381910 -
Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04885998 -
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
|
Phase 1 | |
| Active, not recruiting |
NCT03703297 -
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
|
Phase 3 | |
| Recruiting |
NCT05903092 -
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Terminated |
NCT04422210 -
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
|
Phase 1 | |
| Not yet recruiting |
NCT02875457 -
Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin
|
Phase 3 | |
| Recruiting |
NCT02605811 -
Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
| Completed |
NCT02551432 -
Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02542137 -
Abscopal Effect for Metastatic Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT02262897 -
The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00969306 -
Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients
|
Phase 1 | |
| Completed |
NCT01831089 -
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01943578 -
Value of Physical Capacity Tests in Lung Cancer
|
N/A | |
| Completed |
NCT01497873 -
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00958022 -
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT00930891 -
Bevacizumab in Extensive Small Cell Lung Cancer
|
Phase 2/Phase 3 |